Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.57 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL28237772 | 0.87 | FFAR3 (0.46) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL1164946 | 0.83 | CYP4F2 (0.59) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL7039335 | 0.82 | CYP4F2 (0.40) | CYP4F2CYP4A11ALDH1A1TSHRLMNA | |
| SCHEMBL6461960 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL25808957 | 0.81 | ALDH1A1 (0.50) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL130722 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL2021436 | 0.80 | CYP4F2 (0.67) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL18363110 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL8925795 | 0.79 | CYP4F2 (0.46) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 | |
| SCHEMBL8888149 | 0.79 | CYP4F2 (0.50) | CYP4F2CYP4A11ALDH1A1ABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119735532-A | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-112824380-B | Alpha-fluoro chalcone derivative and application thereof | 杭州百诚医药科技股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| EP-3181564-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2019-09-18 | — | — | EP | disclosed |
| US-9890152-B2 | Aminopyrimidine compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2922851-B1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH INC (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3181564-A1 | AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2809321-B1 | PHENYL-C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION FOR USE IN COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-09 | — | — | EP | disclosed |
| EP-2809321-B1 | PHENYL-C-OXADIAZOLE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE PRODUCTION FOR USE IN COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-11-09 | — | — | EP | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| US-9248187-B2 | Oxadiazole inhibitors of leukotriene production for combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-02 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1517881-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | Syngenta Participations AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
| EP-0900803-B1 | PROCESS FOR THE PREPARATION OF 1-ALKOXY-1-TRIMETHYLSILYLOXYCYCLOPROPANES | IHARA CHEMICAL IND CO (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-5994572-A | REACTING MICROGRANULAR METALLIC SODIUM DISPERSED IN A HYDROCARBON SOLVENT WITH A BETA-HALOGENOCARBOXYLIC ACID ESTER | IHARA CHEMICAL INDUSTRY CO., LTD (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0900803-A1 | PROCESS FOR THE PREPARATION OF 1-ALKOXY-1-TRIMETHYLSILYLOXYCYCLOPROPANES | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0224057-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLIDINE-3-ONES | BASF Aktiengesellschaft (DE) | 1989-08-23 | — | — | EP | disclosed |
| CN-85105429-A | The preparation desugar is the method for the carboxylates derivatives of Aaron Copland peaceful (deglucoteicoplanin) too | — | 1987-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | CYP4F2 1487/4885CYP4A11 591/4885ALDH1A1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.